Vitamin C for septic shock in previous randomized trials: implications of erroneous dosing, timing, and duration

Hyun Jung Lee¹,², Ok-Hyeon Kim¹,², Moon Seong Baek³ and Won-Young Kim³,⁴*

Dear Editor,

We read with interest the article by Rosengrave et al. [1] on a pilot randomized trial to assess the efficacy of intravenous (IV) vitamin C for improving vasopressor requirements and other outcomes in patients with septic shock. They did not observe significant differences in the dose or duration of vasopressor use between the vitamin C and placebo groups. The authors argue that the study was limited by the small sample size (to detect differences in populations with a lower prevalence of vitamin C deficiency), insufficient dosage (median: 8 g/day), and delayed initiation of vitamin C (median: 18 h). Further studies considering these limitations are needed, although we would like to add several issues regarding vitamin C duration and patient heterogeneity.

Previous studies have demonstrated that some patients might experience hypovitaminosis C as early as 48 h after discontinuation of vitamin C infusion, regardless of the dosing regimen [2]. Given that most randomized trials that failed to show a survival benefit of vitamin C limited its use to a maximum of 4 days, sustained therapy may be needed to obtain the favorable effects of vitamin C over time. In the CITRIS-ALI trial that evaluated the benefit of IV vitamin C among patients with sepsis and acute respiratory distress syndrome, the mortality rate was 81% lower in the 4-day treatment group than in the placebo group [3]. However, there was no between-group difference in mortality after treatment cessation. In the study by Rosengrave et al. [1], the dosing regimen may have been “too short” to observe any treatment effects because half of the intervention group did not receive vitamin C for the entire 4 days. We recently assessed the efficacy of vitamin C, hydrocortisone, and thiamine in a murine model of sepsis induced by cecal ligation and puncture (CLP). Vitamin C (45 mg/kg), hydrocortisone (1.5 mg/kg), and thiamine (3 mg/kg) were dissolved in 1 mL lactated Ringer’s solution and administered intravenously starting 6 h after CLP and continued every 12 h for 4 days for a total of 8 doses. Fluid resuscitation and antibiotic therapy (25 mg/kg of imipenem in lactated Ringer’s solution with 5% dextrose starting 6 h after CLP and continued every 12 h for a total of 6 doses) were also provided. Notably, over 50% of control mice died within 3 days of CLP, whereas all treated mice survived the 4-day intervention and only started to die after cessation of intervention (Fig. 1a). Inflammatory biomarkers in serum measured 24 h after CLP (tumor necrosis factor-α) and in hepatocytes harvested 7 days after CLP (heme oxygenase 1 and prostaglandin-endoperoxide synthase 2) were significantly lower in the treated mice than in the control mice (Fig. 1b, c). In addition, hepatocyte swelling and necrosis 7 days after CLP were markedly attenuated in the treated mice (Fig. 1d). These findings are consistent with those in our previous nationwide cohort study that found significantly lower in-hospital mortality in sepsis patients treated with IV vitamin C for ≥ 5 days [4].

In this study, the survival curves of patients who received vitamin C for 1–2 or 3–4 days tended to diverge earlier...
during the course of sepsis than did those of patients treated for ≥ 5 days.

Second, the outcomes of the previous trials may have been influenced by patient heterogeneity. Moreover, vitamin C may be more beneficial in certain sepsis subgroups, such as the “hyperinflammatory” subphenotype [5]. Older (age ≥ 70 years) patients with multiple comorbidities are more likely to be excluded from clinical trials evaluating agents for sepsis, often because of their risk of death irrespective of treatment response. In Rosengrave’s study [1], the median age of the participants was 69 years, and only 15% had comorbidities. However, our data demonstrated that these patients had lower mortality rates when vitamin C was administered [4]. Interestingly, there was no survival benefit in younger patients (< 70 years) and those with fewer comorbidities. One possible explanation for this discrepancy may be that older patients with comorbidities are more likely to have chronic vitamin C deficiency prior to sepsis, and thus, they are theoretically more likely to benefit from vitamin C treatment. Further studies are required to clarify these potential mechanisms.

In addition to the limitations described in the study by Rosengrave et al. [1], other limitations in previous randomized trials of vitamin C for septic shock include short-term vitamin C administration and heterogeneity of the populations. For patients with sepsis or coronavirus disease 2019, two randomized trials (LOVIT-COVID NCT04401150 and C-EASIE NCT04747795) are currently underway to assess the benefit of very high-dose
(200 mg/kg/day) and early (within 6 h after admission) IV administration of vitamin C, respectively. However, their protocols also limit the use of vitamin C for 4 days, which may be unlikely to produce a profound impact on clinical outcomes.

Abbreviations
CLP: Cecal ligation and puncture; IV: Intravenous.

Acknowledgements
Not applicable.

Authors’ contributions
WYK participated in the conception and design of the study. HJL and OHK performed the experiments and analyzed the data. WYK, HJL, and MSB participated in data interpretation. WYK and HJL drafted the manuscript. OHK and MSB helped revise the manuscript for important intellectual content. All authors have read and approved the final manuscript.

Funding
This research was supported by the National Research Foundation of Korea grant funded by the Korea government (Ministry of Science, ICT & Future Planning) (2020R1A2C2011617) and the research grant from Biomedical Research Institute, Chung-Ang University Hospital (2020).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate
Animal studies were approved by the Institutional Animal Care Use Committee (IACUC) of Chung-Ang University (201900071). All animal experiments were performed in accordance with relevant guidelines and regulations.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Anatomy and Cell Biology, Chung-Ang University College of Medicine, Seoul, Republic of Korea. 2 Department of Global Innovative Drugs, The Graduate School of Chung-Ang University, Chung-Ang University, Seoul, Republic of Korea. 3 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea. 4 Biomedical Research Institute, Chung-Ang University Hospital, Seoul, Republic of Korea.

References
1. Rosengrave P, Spencer E, Williman J, Mehrtens J, Morgan S, Doyle T, et al. Intravenous vitamin C administration to patients with septic shock: a pilot randomised controlled trial. Crit Care. 2022;26:26.
2. de Grooth HJ, Manubulu-Choo WP, Zandvliet AS, Spoelstra-de Man AME, Girbes AR, Swart EL, et al. Vitamin C pharmacokinetics in critically ill patients: a randomized trial of four IV regimens. Chest. 2018;153:1368–77.
3. Hemila H, Chalker E. Reanalysis of the effect of vitamin C on mortality in the CITRIS-ALI trial: important findings dismissed in the trial report. Front Med (Lausanne). 2020;7:590853.
4. Jung SY, Lee MT, Baek MS, Kim WY. Vitamin C for ≥ 5 days is associated with decreased hospital mortality in sepsis subgroups: a nationwide cohort study. Crit Care. 2022;26:3.
5. Kim WY, Jung JW, Choi JC, Shin JW, Kim JY. Subphenotypes in patients with septic shock receiving vitamin C, hydrocortisone, and thiamine: a retrospective cohort analysis. Nutrients. 2019;11:2976.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.